Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)
MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its submission entitled "Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease" has been selected for a late breaking poster presentation at the 17th edition of the Clinical Trials on Alzheimer's Disease Conference (CTAD24) to be held October 29 -November 1, 2024 in Madrid, Spain.


"We are excited to have been selected to present important Lomecel-B™ data at a leading forum for Alzheimer's research and clinical investigation," said Wa'el Hashad, CEO of Longeveron. "We believe the findings offer potential mechanistic and clinical insights in the development of cellular-based therapy for Alzheimer's disease."

Late Breaking Poster Presentation

Date: Tuesday, October 29, 2024, 3:00 p.m. CEST to Wednesday, October 30, 5:00 p.m. CEST
Theme: 11. New Therapies and Clinical Trials
Title: LP029 "Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's"
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
3771 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2216Followers
    104Following
    21KVisitors
    Follow